A Phase 4 interventional study of Vedolizumab IV in Colitis, Ulcerative, sponsored by Takeda. Completed at 49 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-07-28.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 12th largest by enrollment, is one of 8 that started in 2017, is one of 15 in phase 4, and was the 16th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 278 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 21st largest by enrollment of the 43 interventional ones that give a count, is one of 8 that started in 2017, is one of 9 in phase 4, and was the 28th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy and safety of vedolizumab intravenous (IV) dose optimization on mucosal healing compared with the standard vedolizumab IV dosing regimen over a 30 week treatment period in participants with moderately to severely active ulcerative colitis (UC) and high vedolizumab clearance, based on a Week 5 predefined serum vedolizumab concentration threshold less than (\<) 50 microgram per milliliter (microg/mL) and who are Week 6 non-responders based on partial Mayo score.
The drug being tested in this study is called Vedolizumab. Vedolizumab will be administered as an IV infusion. It is being tested in this study with new doses. This study will investigate the efficacy and safety of dose optimization of vedolizumab IV, compared with standard dosing of vedolizumab IV, over a 30-week treatment period.
The study will enroll approximately 250 moderately to severely active subjects with UC in order to randomize approximately 100 non-responder subjects with high vedolizumab drug clearance. Subjects will receive induction therapy of vedolizumab IV 300 mg on Day 1 and Week 2 (Lead-in Period). At Week 5, serum vedolizumab concentration will be measured. At Week 6, subjects will be assessed for clinical response based on partial Mayo score.
Results of both Week 5 vedolizumab concentration and Week 6 clinical response will determine the treatment pathway. Those who are non-responders based on partial Mayo score at Week 6 and who are assessed as having high vedolizumab clearance, based on a predefined Week 5 serum vedolizumab concentration threshold (\<50 microg/mL) will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:
All randomized subjects will receive vedolizumab IV either 300 mg or 600 mg every 4 or 8 weeks.
This multi-center trial will be conducted in United States of America and Canada. The overall time to participate in this study is 56 weeks. Subjects will make multiple visits to the clinic, and will be contacted by telephone, 6 months after last dose of study drug for a long term follow-up safety survey.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has demonstrated an inadequate response with, lost response to, or intolerance of at least 1 of the following agents: immunomodulators, , or tumor necrosis factor-alpha (TNF-α) antagonists. Subject who are naive to TNF-α antagonist therapy or who have previously failed TNF-α antagonist therapy (including primary and secondary non-responders or intolerant) may be included.
Week 6 Randomized Treatment Period Inclusion Criteria
Exclusion Criteria:
Has received any of the following for the treatment of underlying disease within 30 days of screening:
Has active or latent tuberculosis (TB), as evidenced by the following:
a. A diagnostic TB test performed within 30 days of screening or during the Screening Period that is positive, defined as: i. Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR ii. A TB skin test reaction ≥ 5 mm OR, b. Chest X-ray within 3 months of screening that is suspicious for pulmonary TB, and a positive or 2 successive indeterminate QuantiFERON tests within 30 days prior to Screening or during the Screening Period.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 300 mg intravenous (IV) infusion once at Day 1 and at Week 2. Participants who were non-responders based on partial Mayo score at Week 6 and who had high vedolizumab clearance (\>0.14 L/day) at Week 5 were eligible for Randomized Treatment Period (RTP). Participants who were responders (Lead-In Failures) entered the 18-week follow-up period and discontinued the study.
Drug: Vedolizumab IV
Following Lead-in Period, participants received vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) at Weeks 6, 14 and 22 as standard treatment plus 18 weeks follow-up.
Drug: Vedolizumab IV
Following Lead-in Period, participants received vedolizumab 600 mg, IV infusion at Week 6, followed by Regimen A: vedolizumab 300 mg once in every 4 weeks (Q4W) thereafter (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up, or Regimen B: vedolizumab 600 mg, IV infusion Q4W (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up based on drug clearance.
Drug: Vedolizumab IV
Vedolizumab intravenous infusion.
Also known as: Entyvio, MLN0002
Percentage of Participants Achieving Mucosal Healing at Week 30
Mucosal healing is defined as Mayo endoscopic subscore \<=1 point. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.
Time frame: Week 30
Percentage of Participants Achieving Clinical Remission at Week 30
Clinical remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point at Week 30. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.
Time frame: Week 30
Percentage of Participants Achieving Clinical Response at Week 30
Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Day 1) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point, at Week 30. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.
Time frame: Week 30
Percentage of Participants Achieving Clinical Response at Week 14
Clinical response is defined as A reduction in partial Mayo score of ≥2 points and ≥25% from Baseline (Day 1) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Mayo score was used in clinical trials to assess UC disease activity. A composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician's global assessment), each scored on a scale from 0 to 3 with total partial Mayo score ranging from 0 to 9 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore.
Time frame: Week 14
Percentage of Participants Achieving Corticosteroid-Free Remission
Participants using oral corticosteroids at Baseline who have discontinued corticosteroids and are in clinical remission. Mayo score was used in clinical trials to assess UC disease activity. Clinical Remission is defined as a complete Mayo score of \<=2 points and no individual subscore \>1 point at Week 30. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.
Time frame: Week 30
Percentage of Participants Achieving Durable Clinical Response
A clinical response (based on partial Mayo score), which is defined as a reduction in partial Mayo score of ≥2 points and ≥25% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point at Weeks 14 and 30. Mayo score was used in clinical trials to assess UC disease activity. A composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician's global assessment), each scored on a scale from 0 to 3 with total partial Mayo score ranging from 0 to 9 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore. Percentage of participants with durable clinical response, clinical response achieved at both Weeks 14 and 30 are reported.
Time frame: Weeks 14 and 30
Participants with ulcerative colitis (UC) took part in the study at 90 investigative sites in the United States and Canada from 29 March 2017 to 16 October 2020.
| Milestone | Lead-in Period: Vedolizumab 300 mg | Randomized Treatment Period (RTP): Standard Treatment Arm | RTP: Dose Optimized Arm |
|---|---|---|---|
| Started | 278 | 0 | 0 |
| Completed | 109 | 0 | 0 |
| Not completed | 169 | 0 | 0 |
| Withdrew: Pretreatment event/adverse event | 8 | 0 | 0 |
| Withdrew: Significant protocol deviation | 12 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Voluntary withdrawal | 6 | 0 | 0 |
| Withdrew: Randomized but not treated | 142 | 0 | 0 |
| Milestone | Lead-in Period: Vedolizumab 300 mg | Randomized Treatment Period (RTP): Standard Treatment Arm | RTP: Dose Optimized Arm |
|---|---|---|---|
| Started | 0 | 54 | 55 |
| Not treated post randomization | 0 | 1 | 0 |
| Safety population | 0 | 53 | 55 |
| Completed | 0 | 31 | 31 |
| Not completed | 0 | 23 | 24 |
| Withdrew: Pretreatment event/adverse event | 0 | 3 | 9 |
| Withdrew: Significant protocol deviation | 0 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 |
| Withdrew: Voluntary withdrawal | 0 | 10 | 1 |
| Withdrew: Lack of efficacy | 0 | 6 | 7 |
| Withdrew: Reason not specified | 0 | 2 | 1 |
Mucosal healing is defined as Mayo endoscopic subscore \<=1 point. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.
| percentage of participants | RTP: Standard Treatment Arm | RTP: Dose Optimized Arm |
|---|---|---|
| Percentage of Participants Achieving Mucosal Healing at Week 30 | 18.9 (9.4 to 32.0) | 14.5 (6.5 to 26.7) |
Clinical remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point at Week 30. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.
| percentage of participants | RTP: Standard Treatment Arm | RTP: Dose Optimized Arm |
|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Week 30 | 9.4 (3.1 to 20.7) | 9.1 (3.0 to 20.0) |
Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Day 1) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point, at Week 30. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.
| percentage of particpants | RTP: Standard Treatment Arm | RTP: Dose Optimized Arm |
|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 30 | 32.1 (19.9 to 46.3) | 30.9 (19.1 to 44.8) |
Clinical response is defined as A reduction in partial Mayo score of ≥2 points and ≥25% from Baseline (Day 1) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Mayo score was used in clinical trials to assess UC disease activity. A composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician's global assessment), each scored on a scale from 0 to 3 with total partial Mayo score ranging from 0 to 9 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore.
| percentage of participants | RTP: Standard Treatment Arm | RTP: Dose Optimized Arm |
|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 14 | 34.0 (21.5 to 48.3) | 40.0 (27.0 to 54.1) |
Participants using oral corticosteroids at Baseline who have discontinued corticosteroids and are in clinical remission. Mayo score was used in clinical trials to assess UC disease activity. Clinical Remission is defined as a complete Mayo score of \<=2 points and no individual subscore \>1 point at Week 30. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.
| percentage of participants | RTP: Standard Treatment Arm | RTP: Dose Optimized Arm |
|---|---|---|
| Percentage of Participants Achieving Corticosteroid-Free Remission | 21.4 (4.7 to 50.8) | 14.3 (3.0 to 36.3) |
A clinical response (based on partial Mayo score), which is defined as a reduction in partial Mayo score of ≥2 points and ≥25% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point at Weeks 14 and 30. Mayo score was used in clinical trials to assess UC disease activity. A composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician's global assessment), each scored on a scale from 0 to 3 with total partial Mayo score ranging from 0 to 9 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore. Percentage of participants with durable clinical response, clinical response achieved at both Weeks 14 and 30 are reported.
| percentage of participants | RTP: Standard Treatment Arm | RTP: Dose Optimized Arm |
|---|---|---|
| Percentage of Participants Achieving Durable Clinical Response | 22.6 (12.3 to 36.2) | 30.9 (19.1 to 44.8) |
Collected over From the first dose of study drug up to 18 weeks after the last dose (approximately 44 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lead-in Period | 1/278 (0.4%) | 12/278 (4.3%) | 10/278 (3.6%) |
| Lead-in Failure Follow-up Period | 0/170 (0%) | 1/170 (0.6%) | 4/170 (2.4%) |
| RTP: Standard Treatment Arm | 0/53 (0%) | 4/53 (7.5%) | 9/53 (17%) |
| RTP: VDZ Dose Optimization: Regimen A | 0/28 (0%) | 4/28 (14.3%) | 12/28 (42.9%) |
| RTP: VDZ Dose Optimization: Regimen B | 0/27 (0%) | 1/27 (3.7%) | 9/27 (33.3%) |
| Event | Lead-in Period | Lead-in Failure Follow-up Period | RTP: Standard Treatment Arm | RTP: VDZ Dose Optimization: Regimen A | RTP: VDZ Dose Optimization: Regimen B |
|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 7/278 | 1/170 | 2/53 | 3/28 | 1/27 |
| Abdominal pain lowerGastrointestinal disorders | 0/278 | 0/170 | 0/53 | 1/28 | 0/27 |
| Benign familial haematuriaCongenital, familial and genetic disorders | 0/278 | 0/170 | 1/53 | 0/28 | 0/27 |
| Clostridium difficile infectionInfections and infestations | 0/278 | 0/170 | 1/53 | 0/28 | 0/27 |
| Viral upper respiratory tract infectionInfections and infestations | 0/278 | 0/170 | 1/53 | 0/28 | 0/27 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/278 | 0/170 | 0/53 | 0/28 | 0/27 |
| Abdominal painGastrointestinal disorders | 1/278 | 0/170 | 0/53 | 0/28 | 0/27 |
| AppendicitisInfections and infestations | 1/278 | 0/170 | 0/53 | 0/28 | 0/27 |
| Clostridium difficile colitisInfections and infestations | 1/278 | 0/170 | 0/53 | 0/28 | 0/27 |
| Deep vein thrombosisVascular disorders | 1/278 | 0/170 | 0/53 | 0/28 | 0/27 |
| Event | Lead-in Period | Lead-in Failure Follow-up Period | RTP: Standard Treatment Arm | RTP: VDZ Dose Optimization: Regimen A | RTP: VDZ Dose Optimization: Regimen B |
|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 2/278 | 2/170 | 4/53 | 0/28 | 3/27 |
| HeadacheNervous system disorders | 8/278 | 1/170 | 1/53 | 3/28 | 2/27 |
| DiarrhoeaGastrointestinal disorders | 0/278 | 0/170 | 0/53 | 3/28 | 2/27 |
| C-reactive protein increasedInvestigations | 1/278 | 1/170 | 3/53 | 1/28 | 2/27 |
| AnaemiaBlood and lymphatic system disorders | 0/278 | 0/170 | 1/53 | 0/28 | 2/27 |
| FatigueGeneral disorders | 0/278 | 0/170 | 1/53 | 1/28 | 2/27 |
| SinusitisInfections and infestations | 0/278 | 0/170 | 1/53 | 0/28 | 2/27 |
| VomitingGastrointestinal disorders | 0/278 | 0/170 | 0/53 | 2/28 | 1/27 |
| Abdominal pain upperGastrointestinal disorders | 0/278 | 0/170 | 0/53 | 2/28 | 0/27 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/278 | 0/170 | 1/53 | 2/28 | 0/27 |
Safety analysis set Included all participants who were enrolled and received at least one dose of study medication.
| Age, Continuous(years) | Lead-in Period: Vedolizumab 300 mg |
|---|---|
| Mean | 40.9 ± 15.11 |
| Sex: Female, Male(Participants) | Lead-in Period: Vedolizumab 300 mg |
|---|---|
| Female | 122 |
| Male | 156 |
| Ethnicity (NIH/OMB)(Participants) | Lead-in Period: Vedolizumab 300 mg |
|---|---|
| Hispanic or Latino | 34 |
| Not Hispanic or Latino | 244 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Lead-in Period: Vedolizumab 300 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 18 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 28 |
| White | 228 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
| Height(cm) | Lead-in Period: Vedolizumab 300 mg |
|---|---|
| Mean | 171.5 ± 9.39 |
| Weight(kg) | Lead-in Period: Vedolizumab 300 mg |
|---|---|
| Mean | 80.41 ± 20.112 |
| Body Mass Index (BMI)(kg/m^2) | Lead-in Period: Vedolizumab 300 mg |
|---|---|
| Mean | 27.24 ± 5.942 |
| Smoking Classification(Participants) | Lead-in Period: Vedolizumab 300 mg |
|---|---|
| Participant has never smoked | 179 |
| Participant is a current smoker | 12 |
| Participant is an ex-smoker | 87 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2017 to primary completion in Oct 2020, 42 months.
Results were first posted in Nov 2021, 1 year after primary completion.
Of 63 phase 4 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 63. This study's 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab